FENC (Fennec Pharmaceuticals) Total Long-Term Assets: $4.94 Mil (As of Mar. 2026)


FENC Fennec Pharmaceuticals Inc FENC
54 GF Score
Price $10.70
GF Value $10.01
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Total Long-Term Assets?

Fennec Pharmaceuticals FENC +3.48% 54 Total Long-Term Assets is $4.94 Mil as of Mar. 2026. GuruFocus rates FENC with a GF Score™ of 54/100 and a GF Value™ of $10.01 (Fairly Valued). The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Fennec Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $4.94 Mil.

Fennec Pharmaceuticals Total Long-Term Assets Related Terms

Fennec Pharmaceuticals Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Fennec Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals Total Long-Term Assets Chart

Fennec Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.21 0.01 0.82 3.51

Fennec Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.43 4.08 3.20 3.51 4.94
FENC
54GF Score
Fennec Pharmaceuticals Inc FENC
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fennec Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $4.94 Mil mean?
Fennec Pharmaceuticals (FENC) has a Total Long-Term Assets of $4.94 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Fennec Pharmaceuticals and its competitors.
Is Fennec Pharmaceuticals' Total Long-Term Assets too high?
Fennec Pharmaceuticals' current Total Long-Term Assets is $4.94 Mil. Overall, Fennec Pharmaceuticals has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' Total Long-Term Assets compare to VRTX and REGN?
Fennec Pharmaceuticals' Total Long-Term Assets of $4.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Fennec Pharmaceuticals and its competitors. Fennec Pharmaceuticals's current Total Long-Term Assets is $4.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (FENC) is currently considered Fairly Valued. The stock's GF Value™ is $10.01, compared to a current price of $10.70 — trading 6.9% above its estimated fair value. The current Total Long-Term Assets is $4.94 Mil. Fennec Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Fennec Pharmaceuticals (FENC), the current Total Long-Term Assets is $4.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fennec Pharmaceuticals (FENC) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of $10.70 is trading 6.9% above its estimated GF Value™ of $10.01. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for FENC:

  • Total Long-Term Assets: $4.94 Mil
  • GF Value™: $10.01 vs. price of $10.70 (6.9% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the FENC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fennec Pharmaceuticals Business Description

Other Exchanges RV41:GermanyFRX:Canada
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
54GF Score

Get the complete analysis for FENC

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.70
Price
$10.01
GF Value